Aim immunotech reports first quarter 2022 financial results and provides corporate update

- first quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors
AIM Ratings Summary
AIM Quant Ranking